Search results
Showing 76 to 90 of 281 results for covid-19
NICE has developed a medtech innovation briefing (MIB) on Butterfly iQ+ for diagnostic ultrasound imaging .
This guideline covers care for adults (aged 18 and over) having elective or emergency surgery, including dental surgery. It covers all phases of perioperative care, from the time people are booked for surgery until they are discharged afterward. The guideline includes recommendations on preparing for surgery, keeping people safe during surgery and pain relief during recovery.
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST34)
Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children.
This guideline aims to increase the uptake of all vaccines provided on the NHS routine UK immunisation schedule by everyone who is eligible. It supports the aims of the NHS Long Term Plan , which includes actions to improve immunisation coverage by GPs (including the changes to vaccinations and immunisations detailed in the 2021/2022 and 2022/23 GP contracts ) and support a narrowing of health inequalities.
Read the biographies for all members of the NICE antimicrobial evaluation committee.
Read the biographies for all members of the NICE antimicrobial evaluation committee.
This evidence summary was produced at the start of the COVID-19 pandemic, when evidence was emerging. It has been withdrawn as the content is no longer relevant. See NICE's COVID-19 rapid guideline: managing COVID-19 for current guidance.
COVID-19 rapid evidence summary: Tocilizumab for COVID-19 (ES33)
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
COVID-19 rapid evidence summary: Sarilumab for COVID-19 (ES34)
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B (TA989)
Evidence-based recommendations on etranacogene dezaparvovec (Hemgenix) for treating moderately severe or severe haemophilia B in adults.
Policies, procedures, reports and codes of practice relating to the governance of NICE.
Evidence-based recommendations on isatuximab (Sarclisa) plus bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma in adults when an autologous stem cell transplant is unsuitable.
Show all sections
COVID-19 rapid evidence summary: vitamin D for COVID-19 (ES28)
This evidence summary has been updated and replaced by the COVID-19 rapid guideline on vitamin D (NG187).
In development Reference number: GID-HTE10073 Expected publication date: 15 September 2026
RespiraSense for continuously monitoring respiratory rate (MIB299)
NICE has developed a medtech innovation briefing (MIB) on RespiraSense for continuously monitoring respiratory rate .